Results 41 to 50 of about 1,302,607 (412)

Key Learning Outcomes for Clinical Pharmacology and Therapeutics Education in Europe: A Modified Delphi Study

Clinical pharmacology and therapy, 2018
Harmonizing clinical pharmacology and therapeutics (CPT) education in Europe is necessary to ensure that the prescribing competency of future doctors is of a uniform high standard.
D. Brinkman, J. Tichelaar, L. Mokkink, T. Christiaens, R. Likić, R. Mačiulaitis, João N. Costa, E. Sanz, S. Maxwell, M. Richir, M. V. van Agtmael, Romain Ivanka Maria Ivanka Emil Gayla Dinko Suzana Greta Lefebvre Kostadinova Ganeva Atanasova Gatchev Stav, Romain Lefèbvre, Iva S. Kostadinova, M. Ganeva, I. Atanasova, E. Gatchev, G. Stavreva, D. Vitezić, S. Matanović, G. Wozniak, Persoulla A Nicolaou, K. Urbánek, O. Slanař, E. Kmoníčková, R. Demlova, T. Bergmann, P. Damkier, A. Kalda, R. Huupponen, J. Backman, M. Drici, D. Deplanque, M. Molimard, E. Toussirot, Y. Pers, P. Bertin, B. Laviolle, C. Le Jeunne, P. Saulnier, B. Chamontin, M. Roustit, D. Orlikowski, Nicolas Simon, P. Dequin, T. Angoulvant, Juliane Bolbrinker, L. Wojnowski, I. Cascorbi, Frank Müller, Slike Müller, M. Schwaninger, J. Neumann, F. Stümpel, R. Regenthal, U. Fuhr, P. Thürmann, A. Eirini, Paraskevi Papaioannidou, D. Kouvelas, G. Kolios, P. Riba, D. Kerins, David Williams, A. Harnett, E. Spina, G. Fumagalli, A. Filippelli, S. Benemei, F. De Ponti, M. Cosentino, V. Locatelli, M. D. De Montis, M. Memo, E. Raschi, S. Purviņa, J. Gulbinovič, J. Mifsud, K. Keijsers, R. Rissmann, G. Dumont, F. van Rosse, O. Spigset, M. S. Opdal, J. Braszko, D. Mirowska-Guzel, M. Broncel, I. Kocić, M. C. Sousa, E. Monteiro, L. Dima, I. Magyar, S. Conea, A. Buzoianu, H. Glasová, J. Tisoňová, Josef Glasa, M. Kržan, Joaquín Sáez-Peñataro, F. J. de Abajo Iglesias, D. Capellà, F. Figuerola, A. C. Sansuán, M. López-Rico, G. Manso, Julio Benitez, M. Lucena, M. L. Bernal, X. C. Cladellas, Ruth Aparicio Hernandez, C. Pontes, G. Panagiotidis, Y. Böttiger, S. Wallerstedt, A. Eriksson, J. Desmeules, S. Krähenbühl, Rick Plumb, M. Okorie, K. Wilson, G. Mckay, R. Sofat, V. Kapil, J. Whitfield, R. Thanacoody, Fraz Mir, Y. Loke, M. Schachter, Lauren O'brien, A. Heep   +129 more
semanticscholar   +1 more source

Effects of paracetamol (acetaminophen) on gene expression and permeability properties of the rat placenta and fetal brain [version 2; peer review: 2 approved]

F1000Research, 2020
Background: Paracetamol (acetaminophen) is widely used in pregnancy and generally regarded as “safe” by regulatory authorities. Methods: Clinically relevant doses of paracetamol were administered intraperitoneally to pregnant rats twice daily from ...
Liam M. Koehn, Yifan Huang, Mark D Habgood, Kai Kysenius, Peter J. Crouch, Katarzyna M Dziegielewska, Norman R Saunders   +6 more
doaj   +1 more source

The European Association for Clinical Pharmacology and Therapeutics—25 years’ young and going strong

European Journal of Clinical Pharmacology, 2019
Clinical pharmacology as a scientific discipline and medical specialty was unarguably born in the twentieth century. Whilst pharmacology—the science behind the treatment of disease—had been in evolution since at least medieval times, the clinical ...
J. Coleman, C. Samer, M. Zeitlinger, M. V. van Agtmael, G. Rongen, P. Marquet, T. Simon, D. Singer, V. Manolopoulos, Y. Böttiger   +9 more
semanticscholar   +1 more source

Antibody-loading of biological nanocarrier vesicles derived from red-blood-cell membranes [PDF]

arXiv, 2023
Antibodies, disruptive potent therapeutic agents against pharmacological targets, face a barrier crossing immune-system and cellular-membranes. To overcome these, various strategies have been explored including shuttling via liposomes or bio-camouflaged nanoparticles.
arxiv  

Identifying glycan consumers in human gut microbiota samples using metabolic labeling coupled with fluorescence-activated cell sorting

Nature Communications, 2023
Dietary glycans are a major driver of the human gut microbiota composition. Here, the authors apply next-generation metabolic labeling coupled with fluorescence-activated cell sorting to identify and isolate gut bacteria consumers of dietary glycans in ...
Lharbi Dridi, Fernando Altamura, Emmanuel Gonzalez, Olivia Lui, Ryszard Kubinski, Reilly Pidgeon, Adrian Montagut, Jasmine Chong, Jianguo Xia, Corinne F. Maurice, Bastien Castagner   +10 more
doaj   +1 more source

Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies [PDF]

, 2017
Background The goal of hepatorenal syndrome type 1 (HRS-1) treatment is to improve renal function. Terlipressin, a synthetic vasopressin analogue, is a systemic vasoconstrictor used for the treatment of HRS-1, where it is available.
Araya, V., Boyer, T. D., Escalante, S., Frederick, R. T., Jamil, K., Pappas, S. C., Reddy, K. R., Rossaro, L., Sanyal, A. J., Teuber, P., Vargas, H. E., Wong, F.   +11 more
core   +2 more sources

A pharmacokinetic -- viral kinetic model describes the effect of alisporivir monotherapy or in combination with peg-IFN on 2 hepatitis C virologic response [PDF]

Clinical Pharmacology and Therapeutics, American Society for Clinical Pharmacology and Therapeutics, 2014, 96 (5), pp.599-608, 2015
Alisporivir is a cyclophilin inhibitor with demonstrated in vitro and in vivo activity against hepatitis C 11 virus (HCV). We estimated antiviral effectiveness of alisporivir alone or in combination with 12 pegylated-Inteferon (peg-IFN) in 88 patients infected with different HCV genotypes treated for four 13 weeks.
arxiv   +1 more source

Standard PK/PD concepts can be applied to determine a dosage regimen for a macrolide: the case of tulathromycin in the calf [PDF]

, 2016
The pharmacokinetic (PK) profile of tulathromycin, administered to calves subcutaneously at the dosage of 2.5 mg/kg, was established in serum, inflamed (exudate), and noninflamed (transudate) fluids in a tissue cage model. The PK profile of tulathromycin
Aliabadi, Anonymous, Bosnar, Committee for Medicinal Products for Human Use (CHMP), Committee for Medicinal Products for Veterinary Use (CVMP), Evans, Gladue, Godinho, Godinho, Higgins, Huang, Karlsson, Kiem, Lees, Mandell, Menge, Mouton, Muller, Nowakowski, Roof, Sarasola, Schentag, Scheuch, Scorneaux, Scorneaux, Sidhu, Thomas, Toutain, Toutain, Toutain, Toutain, Villarino, Villarino, Villarino, Villarino, Waag   +35 more
core   +1 more source

Muscle‐directed gene therapy corrects Pompe disease and uncovers species‐specific GAA immunogenicity

EMBO Molecular Medicine, 2021
Pompe disease is a severe disorder caused by loss of acid α‐glucosidase (GAA), leading to glycogen accumulation in tissues and neuromuscular and cardiac dysfunction. Enzyme replacement therapy is the only available treatment. AT845 is an adeno‐associated
Michelle Eggers, Charles H Vannoy, Jianyong Huang, Pravinkumar Purushothaman, Jacqueline Brassard, Carlos Fonck, Hui Meng, Mariah J Prom, Michael W Lawlor, Justine Cunningham, Chanchal Sadhu, Fulvio Mavilio   +11 more
doaj   +1 more source

Pharmacology and Therapeutics Education in the European Union Needs Harmonization and Modernization: A Cross‐sectional Survey Among 185 Medical Schools in 27 Countries

Clinical pharmacology and therapy, 2017
Effective teaching in pharmacology and clinical pharmacology and therapeutics (CPT) is necessary to make medical students competent prescribers. However, the current structure, delivery, and assessment of CPT education in the European Union (EU) is ...
D. Brinkman, J. Tichelaar, M. Okorie, L. Bissell, T. Christiaens, R. Likić, R. Mačiulaitis, José Abrão Cardeal da Costa, E. J. Sanz, Bi Tamba, S. Maxwell, M. Richir, M. V. Agtmael   +12 more
semanticscholar   +1 more source